AR092198A1 - Derivados de pirazolopirimidinas - Google Patents
Derivados de pirazolopirimidinasInfo
- Publication number
- AR092198A1 AR092198A1 ARP130102974A AR092198A1 AR 092198 A1 AR092198 A1 AR 092198A1 AR P130102974 A ARP130102974 A AR P130102974A AR 092198 A1 AR092198 A1 AR 092198A1
- Authority
- AR
- Argentina
- Prior art keywords
- pirazolopirimidinas
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261692853P | 2012-08-24 | 2012-08-24 | |
US201361774094P | 2013-03-07 | 2013-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092198A1 true AR092198A1 (es) | 2015-04-08 |
Family
ID=49085221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102974 AR092198A1 (es) | 2012-08-24 | 2013-08-22 | Derivados de pirazolopirimidinas |
Country Status (26)
Country | Link |
---|---|
US (5) | US9555036B2 (es) |
EP (1) | EP2888264B1 (es) |
JP (1) | JP6196674B2 (es) |
KR (1) | KR20150046267A (es) |
CN (1) | CN104755480B (es) |
AR (1) | AR092198A1 (es) |
AU (1) | AU2013305790B2 (es) |
BR (1) | BR112015003259A2 (es) |
CA (1) | CA2880576A1 (es) |
CL (1) | CL2015000408A1 (es) |
CR (1) | CR20150061A (es) |
DO (1) | DOP2015000027A (es) |
EA (1) | EA026354B1 (es) |
ES (1) | ES2653254T3 (es) |
HK (1) | HK1211029A1 (es) |
IL (1) | IL236983B (es) |
MX (1) | MX359671B (es) |
MY (1) | MY175676A (es) |
NZ (1) | NZ704224A (es) |
PE (1) | PE20150730A1 (es) |
PH (1) | PH12015500401B1 (es) |
SG (1) | SG11201500787YA (es) |
TW (1) | TWI625331B (es) |
UA (1) | UA114109C2 (es) |
UY (1) | UY34987A (es) |
WO (1) | WO2014031815A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
PL2734186T3 (pl) | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozycja |
SG11201500787YA (en) * | 2012-08-24 | 2015-03-30 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
JP6228223B2 (ja) | 2012-11-20 | 2017-11-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規化合物 |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
CN110772523B (zh) * | 2019-11-07 | 2020-06-26 | 黑龙江中医药大学 | 一种用于防治肾病的药物组合物 |
CN115151547A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
WO2021154667A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115135655A (zh) | 2020-01-27 | 2022-09-30 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
EP4097104A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
CN115643805A (zh) | 2020-01-27 | 2023-01-24 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
JP2023512205A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
CN115279765A (zh) | 2020-01-27 | 2022-11-01 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
US20230348468A1 (en) | 2020-01-27 | 2023-11-02 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
US6627645B2 (en) | 2000-04-28 | 2003-09-30 | Acadia Pharmaceuticals, Inc. | Muscarinic agonists |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
DK1348707T3 (da) | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
CA2484921A1 (en) | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
US6713241B2 (en) | 2002-08-09 | 2004-03-30 | Eastman Kodak Company | Thermally developable emulsions and imaging materials containing binder mixture |
EP1539783B1 (en) * | 2002-08-21 | 2011-04-13 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside phosphorylases and nucleosidases |
US7754728B2 (en) | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
US20060148805A1 (en) | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
EA200600540A1 (ru) | 2003-09-05 | 2006-08-25 | Анадис Фармасьютикалз, Инк. | Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с |
CA2540598C (en) | 2003-10-03 | 2013-09-24 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
JP4472693B2 (ja) * | 2004-03-26 | 2010-06-02 | 大日本住友製薬株式会社 | 9置換−8−オキソアデニン化合物 |
US20070225303A1 (en) | 2004-03-26 | 2007-09-27 | Haruhisa Ogita | 8-Oxoadenine Compound |
BRPI0509576A (pt) | 2004-04-02 | 2007-05-29 | Osi Pharm Inc | composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica |
MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
JP2007530579A (ja) * | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP1888587A1 (en) | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
NZ540160A (en) | 2005-05-20 | 2008-03-28 | Einstein Coll Med | Inhibitors of nucleoside phosphorylases |
US20090234117A1 (en) * | 2005-05-27 | 2009-09-17 | Toshihiko Kashiwagi | Pyrazolopyrimidine Derivative |
US7932257B2 (en) | 2005-07-22 | 2011-04-26 | Sunesis Pharmaceuticals, Inc. | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
BRPI0615307A2 (pt) | 2005-08-25 | 2009-08-04 | Schering Corp | agonistas de adrenorreceptor alfa2c |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
US20100152230A1 (en) | 2005-09-02 | 2010-06-17 | Pfizer Inc. | Hydroxy substituted 1h-imidazopyridines and methods |
TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
WO2007034916A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
EP1939199A4 (en) | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
JPWO2007034917A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
WO2007034881A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
ES2374455T3 (es) | 2006-02-17 | 2012-02-16 | Pfizer Limited | Derivados de 3-deazapurinza como moduladores de tlr7. |
WO2007110368A1 (de) | 2006-03-24 | 2007-10-04 | Siemens Aktiengesellschaft | Verfahren zum betrieb einer verdichtereinheit, verdichtereinheit |
WO2007110868A2 (en) | 2006-03-28 | 2007-10-04 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
DK2038290T3 (da) | 2006-07-07 | 2013-12-02 | Gilead Sciences Inc | Modulatorer af toll-lignende receptor 7 |
TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
WO2008101867A1 (en) | 2007-02-19 | 2008-08-28 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
ES2457316T3 (es) | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
ES2373616T3 (es) | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
MX2009013832A (es) | 2007-06-29 | 2010-03-10 | Gilead Sciences Inc | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
AU2008287421A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Nitrogen containing bicyclic chemical entities for treating viral infections |
PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
KR101649881B1 (ko) | 2008-08-11 | 2016-08-30 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
WO2010018131A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
JP5519670B2 (ja) | 2008-08-11 | 2014-06-11 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
WO2010083725A1 (zh) | 2009-01-20 | 2010-07-29 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
CN102469790B (zh) | 2009-08-07 | 2014-12-03 | 葛兰素史密丝克莱恩生物有限公司 | 脂质化氧代腺嘌呤衍生物 |
WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
ES2525826T3 (es) | 2010-02-10 | 2014-12-30 | Glaxosmithkline Llc | Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
CA2825599C (en) | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors |
EP2670244B1 (en) | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
PL2734186T3 (pl) | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozycja |
SG11201500787YA (en) * | 2012-08-24 | 2015-03-30 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
JP6228223B2 (ja) | 2012-11-20 | 2017-11-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規化合物 |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
EP3107915B1 (en) | 2014-02-20 | 2017-11-08 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
-
2013
- 2013-08-22 SG SG11201500787YA patent/SG11201500787YA/en unknown
- 2013-08-22 UA UAA201501077A patent/UA114109C2/uk unknown
- 2013-08-22 EP EP13756249.2A patent/EP2888264B1/en active Active
- 2013-08-22 TW TW102130088A patent/TWI625331B/zh not_active IP Right Cessation
- 2013-08-22 AU AU2013305790A patent/AU2013305790B2/en not_active Ceased
- 2013-08-22 MX MX2015002433A patent/MX359671B/es active IP Right Grant
- 2013-08-22 MY MYPI2015700519A patent/MY175676A/en unknown
- 2013-08-22 US US14/423,400 patent/US9555036B2/en active Active
- 2013-08-22 CN CN201380055759.3A patent/CN104755480B/zh not_active Expired - Fee Related
- 2013-08-22 AR ARP130102974 patent/AR092198A1/es unknown
- 2013-08-22 UY UY0001034987A patent/UY34987A/es not_active Application Discontinuation
- 2013-08-22 BR BR112015003259A patent/BR112015003259A2/pt not_active Application Discontinuation
- 2013-08-22 ES ES13756249.2T patent/ES2653254T3/es active Active
- 2013-08-22 PE PE2015000238A patent/PE20150730A1/es active IP Right Grant
- 2013-08-22 EA EA201590189A patent/EA026354B1/ru not_active IP Right Cessation
- 2013-08-22 US US13/973,466 patent/US9173872B2/en active Active
- 2013-08-22 JP JP2015528644A patent/JP6196674B2/ja not_active Expired - Fee Related
- 2013-08-22 KR KR1020157007428A patent/KR20150046267A/ko not_active Application Discontinuation
- 2013-08-22 CA CA2880576A patent/CA2880576A1/en not_active Abandoned
- 2013-08-22 WO PCT/US2013/056107 patent/WO2014031815A1/en active Application Filing
- 2013-08-22 NZ NZ704224A patent/NZ704224A/en not_active IP Right Cessation
-
2015
- 2015-01-29 IL IL236983A patent/IL236983B/en active IP Right Grant
- 2015-02-09 CR CR20150061A patent/CR20150061A/es unknown
- 2015-02-12 DO DO2015000027A patent/DOP2015000027A/es unknown
- 2015-02-20 CL CL2015000408A patent/CL2015000408A1/es unknown
- 2015-02-24 PH PH12015500401A patent/PH12015500401B1/en unknown
- 2015-10-01 US US14/872,620 patent/US9662336B2/en not_active Expired - Fee Related
- 2015-12-02 HK HK15111867.0A patent/HK1211029A1/xx unknown
-
2017
- 2017-04-26 US US15/497,852 patent/US10022442B2/en active Active
-
2018
- 2018-06-14 US US16/008,421 patent/US20180289800A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR22C1047I2 (fr) | Derives de benzimidazole-proline | |
SMT201700065B (it) | Derivato piridonico | |
AR092198A1 (es) | Derivados de pirazolopirimidinas | |
CO7061086A2 (es) | Combinaciones de compuestos activos | |
CO7010838A2 (es) | Compuestos de imidazopirrolidinona | |
DK2859055T3 (da) | Polymercoatings | |
DK2825087T3 (da) | Otoscanner | |
DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
CO6990736A2 (es) | Pirrolidina-2-carboxamidas sustituídas | |
DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
DE112012006109A5 (de) | Okklusionsschienenanordnung | |
DK2854722T3 (da) | Stomipose | |
DK2900645T3 (da) | Herbicidt aktive 3-phenylisoxazolinderivater | |
CO7020919A2 (es) | Derivados de tetrahidro-quinazolinona | |
DK3450434T3 (da) | Deutererede derivater af ruxolitinib | |
DK2825157T3 (da) | Aminosyrelipider | |
CO6960557A2 (es) | Derivados de 2-yodo-imidazol | |
DK2831122T3 (da) | Anthocyanidin-kompleks | |
DE112012006214T8 (de) | Wulstringwickler | |
CO7020920A2 (es) | Derivado de fenilazol sustituido | |
DE112012005566T8 (de) | Seltenerdnanoverbundmagnet | |
FR2987600B1 (fr) | Nacelle aplatie de turboreacteur | |
CO6852074A2 (es) | Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida | |
DK2885638T3 (da) | Molekylenet | |
ES1080381Y (es) | Fachada de medios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |